NCT/Study#
NCT03420183 /
ONCTERNAL-CIRM-0001
A Phase 1b-2 Study Of The ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), And The Bruton Tyrosine Kinase Inhibitor, Ibrutinib, In Patients With B-Cell Lymphoid Malignancies
DISEASE GROUP:
Lymphoma
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
